long intergenic non-protein coding RNA 592Genealiases: []
Q-omics provides the consensus-scored LINC00592 profile across patient tissues and cancer cell-line models. LINC00592 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC00592 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, LINC00592 RNA expression shows 13,083 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where LINC00592 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00592 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00592 survival associations across molecular data types. LINC00592 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00592 RNA expression–survival associations across cancer types. High LINC00592 expression shows unfavorable associations in KIRC, UVM, MESO, DLBC and LUAD, but favorable associations in OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC00592 RNA expression.
This table summarizes LINC00592 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00592. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00592 shows higher tumor expression in KIRP, COAD, LUSC, HNSC, BLCA and LUAD. The KIRP box plot shows higher LINC00592 RNA expression in tumor versus normal tissue (log2 FC = +0.274, t-test p < 0.001).
This table shows molecular features associated with LINC00592 in patient tissues and cancer cell lines. In patient samples, LINC00592 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
